
To evaluate outcome after zzso zzso zzso zzso and zzso daily zzso zzso in patients with zzso zzso 

Twenty-five patients with zzso or progressive zzso were treated with zzso in combination with zzso at the Department of zzso zzso University of zzso zzso zzso at primary diagnosis included zzso zzso in 7 patients zzso grade III zzso in 10 patients zzso and zzso in 8 patients zzso All patients had undergone at least one zzso zzso which was complete in 5 patients zzso zzso in 13 patients zzso and a biopsy only in 7 patients zzso zzso patients zzso had undergone zzso zzso for tumor zzso All patients had received radiation therapy with a median dose of 60 zzso The median time zzso between primary zzso and zzso was 36 zzso Using zzso we applied a median total dose of 36 zzso in a median zzso of 5 zzso 2 zzso zzso with zzso was applied in a median dose of 50 zzso 

Median overall survival was 59 zzso Median survival from zzso was 8 zzso zzso survival rates at 6 and 12 months were zzso and zzso Median zzso was 5 zzso zzso zzso rates at 6 and 12 months were zzso and zzso Treatment could be completed in all patients as scheduled without interruptions zzso zzso No severe zzso side effects could be zzso 

zzso and zzso is safe and effective in a zzso of patients with zzso zzso Further evaluation of zzso regimens for zzso or progressive zzso is zzso 

